-transparent.png){kind=logo}
New inhibitors have been designed for cdc2 kinase based on a multiple pseudosubstrate structure. The new inhibitors have three different structural components: 3,4-bis(indol-3-yl)maleimide, Ac-Cys-(Ser)-Pro-Lys-Lys-NHMe, and ethyloxy group between the two components. Inhibitory activities toward cdc2 and other protein kinases were investigated, and the compound (21) with Ac-Cys-Pro-Lys-Lys-NHMe connected with the triethylene glycol spacer exhibited the most potent inhibition with relatively high selectivity.
Related Publications
S Sasaki, and
T Hashimoto, and
N Obana, and
H Yasuda, and
Y Uehara, and
M Maeda
January 1991,
Methods in enzymology,
S Sasaki, and
T Hashimoto, and
N Obana, and
H Yasuda, and
Y Uehara, and
M Maeda
January 2002,
Pharmacology & therapeutics,
S Sasaki, and
T Hashimoto, and
N Obana, and
H Yasuda, and
Y Uehara, and
M Maeda
May 1997,
Cancer research,
S Sasaki, and
T Hashimoto, and
N Obana, and
H Yasuda, and
Y Uehara, and
M Maeda
August 1995,
The Biochemical journal,
S Sasaki, and
T Hashimoto, and
N Obana, and
H Yasuda, and
Y Uehara, and
M Maeda
July 2011,
Bioorganic & medicinal chemistry letters,
S Sasaki, and
T Hashimoto, and
N Obana, and
H Yasuda, and
Y Uehara, and
M Maeda
June 2021,
Journal of medicinal chemistry,
S Sasaki, and
T Hashimoto, and
N Obana, and
H Yasuda, and
Y Uehara, and
M Maeda
February 2015,
Bioorganic & medicinal chemistry letters,
S Sasaki, and
T Hashimoto, and
N Obana, and
H Yasuda, and
Y Uehara, and
M Maeda
January 2007,
Current topics in medicinal chemistry,
S Sasaki, and
T Hashimoto, and
N Obana, and
H Yasuda, and
Y Uehara, and
M Maeda
January 2009,
Current topics in medicinal chemistry,
S Sasaki, and
T Hashimoto, and
N Obana, and
H Yasuda, and
Y Uehara, and
M Maeda
November 2017,
Bioorganic & medicinal chemistry letters,
